$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
尼拉帕尼多少钱
2025-10-19 11:44:20
Check Details
尼拉帕尼价格贵吗
2025-10-19 11:44:20
Check Details
奥拉帕尼和尼拉帕尼是一种药吗
2025-10-19 11:44:20
Check Details
奥拉帕尼和尼拉帕尼的区别
2025-10-19 11:44:20
Check Details
晚期BRCA突变卵巢癌随访五年,一半患者无疾病进展!
2025-10-19 11:44:20
Check Details
尼拉帕尼一线维持治疗晚期卵巢癌,疾病进展或死亡风险显著降低38%!
2025-10-19 11:44:20
Check Details
SOLO1试验5年随访:奥拉帕尼治疗BRCA突变的晚期卵巢癌效果显著
2025-10-19 11:44:20
Check Details
曲贝替定图片及介绍
2025-10-19 11:44:20
Check Details
曲贝替定多少钱一盒呢?
2025-10-19 11:44:20
Check Details
曲贝替定2020价格
2025-10-19 11:44:20
Check Details
曲贝替定中国有卖吗?
2025-10-19 11:44:20
Check Details
曲贝替定可治疗哪些疾病?
2025-10-19 11:44:20
Check Details
1
2
...
6930
6931
6932
6933
6934
6935
6936
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
2
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
3
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
4
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
5
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
6
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
7
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
8
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
9
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
10
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
11
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
12
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance